bioMérieux's GENE-UP® CAMPYLOBACTER Selected as Method of Choice by USDA-FSIS

In-vitro diagnostics company's assay chosen by USDA-FSIS for Campylobacter detection in USDA Food Safety and Inspection Service Laboratories.

Bmx Campylobacter Cover Image

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

bioMérieux, an expert in the field of in vitro diagnostics, is pleased to announce the incorporation of the company’s GENE-UP® CAMPYLOBACTER assay into the methodology used by the USDA-FSIS Field Service Laboratories.  

"We are thrilled to be awarded this contract by the USDA-FSIS. With the inclusion of GENE-UP® CAMPYLOBACTER, bioMérieux now has the most FSIS methods of choice for microbiology than any other diagnostics provider," says Miguel Villa, Sr. Vice President, Americas, Industrial Applications, at bioMérieux. "This is a testament to our continued dedication to providing innovation within the animal protein sector and the food industry at large, reinforcing GENE-UP® as the full solution for all molecular testing needs in one place.” 

The GENE-UP® CAMPYLOBACTER assay is the latest of bioMérieux’s molecular diagnostic solutions to be recognized by food safety regulatory bodies in the United States. Earlier this year, bioMérieux announced a research collaboration to improve microbial detection of food-borne pathogens with the Food and Drug Administration, and in 2022, the USDA named bioMérieux’s GENE-UP® QUANT Salmonella quantification method of choice in all FSIS laboratories, with both GENE-UP® QUANT Salmonella and TEMPO® solutions currently included in the USDA Microbiology Laboratory Guidebook (MLG).

“Our Augmented Diagnostics approach helps food industry leaders go beyond the test results and harness data, genomics, and diagnostic insights to solve the toughest problems,” says John Shultz, Sr. Director, Sales and Marketing, Industrial Applications, at bioMérieux. “The recognition of GENE-UP® CAMPYLOBACTER as the method of choice of the USDA is yet another way that bioMérieux helps facilitate and advance the science of food safety and protect public health.” 

A longtime diagnostic partner to the food industry, bioMérieux works closely with its customers to develop solutions that go beyond the test results, providing smarter, more dynamic solutions that provide actionable insights with unrivaled specificity to each production facility. Its complete portfolio of industry solutions supports the entirety of the production process, from pathogen detection, to quantification, to enumerating quality indicators. 

GENE-UP® CAMPYLOBACTER is one of many bioMérieux testing innovations to be incorporated as an industry standard. bioMérieux continues to develop new solutions that tackle the food industry’s toughest challenges with cutting-edge services and solutions.

Fill out the form below to request more information about bioMérieux's GENE-UP® CAMPYLOBACTER Selected as Method of Choice by USDA-FSIS
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report